Crossmark

The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience

Crossref DOI link: https://doi.org/10.1007/s11060-023-04496-z

Published Online: 2023-11-13

Published Print: 2023-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zamarud, Aroosa

Marianayagam, Neelan J.

Park, David J.

Yener, Ulas

Yoo, Kelly H.

Meola, Antonio

Chang, Steven D.
License Information

Text and Data Mining valid from 2023-11-01

Version of Record valid from 2023-11-01
More Information

Article History

Received: 26 September 2023

Accepted: 1 November 2023

First Online: 13 November 2023

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below